MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • August 2018

AIVITA Biomedical Appoints Chief Financial Officer and Vice President of Business Development

AIVITA Biomedical Announces Initiation of First Clinical Site for ROOT OF CANCER Glioblastoma Trial

AIVITA Biomedical to Speak and Exhibit Skincare Products at August Aesthetics Conferences

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Announces Case Report Suggesting Positive Collateral Benefits in Systemic Lupus Erythematosus Achieved Through the Use of Its Dendritic Cell Vaccine Kit
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Advanced Therapies Europe
  • AIVITA Biomedical CEO Dr. Hans Keirstead Awarded OC50 Honor by The Orange County Business Journal
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Present at World Vaccine Congress

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.